Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

South Korea PM vouches for AstraZeneca vaccine safety ahead of first shipments

Published 02/19/2021, 03:06 AM
Updated 02/19/2021, 03:11 AM
© Reuters. FILE PHOTO: A nurse takes part in the coronavirus disease (COVID-19) vaccination mock drill at the COVID-19 vaccination center in Seoul

By Sangmi Cha

SEOUL (Reuters) - South Korea's prime minister assured there were no safety issues with AstraZeneca (NASDAQ:AZN)'s coronavirus vaccine on Friday, as the government held final drills ahead of next week's scheduled rollout of the first vaccines.

The AstraZeneca vaccine, which was developed with Britain's Oxford University, was the first to win approval in South Korea, but it has been dogged by questions over its efficacy among older people and concerns over side effects.

"The vaccine was granted approval in around 50 countries and recently got emergency approval from the World Health Organization," said Prime Minister Chung Sye-kyun. "I repeat, there is no issue with safety."

The authorities have said they will not use the British vaccine on people aged 65 and older until more efficacy data becomes available, reversing an earlier decision.

Health authorities in some European countries are facing resistance to AstraZeneca's vaccine after side effects led hospital staff and other front-line workers to call in sick.

Some South Korean health care workers, who are first in line to receive the vaccine next week, have expressed similar concerns, amid worries and uncertainty among the broader public.

A Gallup Korea survey released on Friday found that 71% of respondents were worried about vaccine side effects, but an equal number said they would nevertheless get a vaccine when it becomes available.

The country's drug safety ministry granted final approval for a shipment of 1.57 million doses of the AstraZeneca/Oxford coronavirus vaccine this week, as authorities gear up to begin vaccinating health care workers on Feb. 26.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Aside from AstraZeneca, South Korea has also reached agreements with Pfizer/BioNTech, Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX) Inc, Johnson & Johnson (NYSE:JNJ), and global vaccine-sharing scheme COVAX, for the supply of their vaccines.

Plans call for about 10 million high-risk people to be inoculated by July with the aim to reach herd immunity by November. The chief of the South Korean Medical Association and some experts have cast doubt on that timeline, calling it practically an impossible goal.

The defence ministry in charge of transport of the vaccine held a drill on Friday to practice shipping the AstraZeneca products to a local clinic.

The military mobilised its army, navy and the air force to move the shots from SK Chemical's drugmaker arm SK bioscience's production facility in Andong city, some 100 kilometres (62 miles) southeast of Seoul, across the country. The drill also involved military aircraft and helicopters to deliver to Jeju island.

As of midnight Thursday, there were 561 new coronavirus cases, bringing the total to 86,128 with 1,550 deaths, the Korea Disease Control and Prevention Agency (KDCA) said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.